Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Carboplatin and piroxicam in transitional cell carcinoma of the bladder
Invasive transitional cell carcinoma (TCC) of the urinary bladder is not too rare and unfortunately responds poorly to medical therapy. Combining platinum chemotherapy with a cyclooxygenase (cox) inhibitor has shown promise against canine TCC, where the disease closely mimics the human condition. Here is a new interesting study!

A phase II clinical trial of carboplatin combined with the cox inhibitor, piroxicam, was performed in 31 dogs with naturally occurring, histopathologically confirmed, measurable TCC.

Complete tumour staging was performed before and at 6-week intervals during therapy. Tumour responses in 29 dogs included 11 partial remissions, 13 stable disease and five progressive disease.

Two of the 31 dogs were withdrawn prior to the re-staging of the tumour. Gastrointestinal toxicity was observed in 23 dogs.

Hematologic toxicity was noted in 11 dogs.

The median survival was 161 days from first carboplatin treatment to death.

In conclusion, carboplatin/piroxicam induced remission in 40% of dogs providing evidence that a cox inhibitor enhances the antitumour activity of carboplatin.

The frequent toxicity and limited survival, however, do not support the use of this specific protocol against TCC.


Source: Boria, P. A., Glickman, N. W., Schmidt, B. R., Widmer, W. R., Mutsaers, A. J., Adams, L. G., Snyder, P. W., DiBernardi, L., de Gortari, A. E., Bonney, P. L. & Knapp, D. W. (2005): Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. In: Veterinary and Comparative Oncology 3 (2), 73-80.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Vocal fold granulomas in brachycephalic dogsmembers
Vocal cord granulomas are rarely observed in brachycephalic breeds but often reported in humans as contact granulomas. Six French bulldogs were included in this retrospective descriptive study. A very informative new study adding new Information to the brachycephalic airway Syndrome.

  • Extracellular vesicles in mammary cancer of dogs and catsmembers
  • Immunocytochemical assay using aqueous humor to diagnose feline infectious peritonitis members
  • Microbiota of traumatic, open fracture wounds and the mechanism of injury members
  • False-positive CT and radiography results for bronchial collapse in healthy dogsmembers
  • Variability of SDMA in apparently healthy dogsmembers
  • Bioavailability of suppository acetaminophen in dogsmembers
  • Computed tomographic lymphography for lymph node staging in dogs with malignant tumors members
  • Characterization of ocular melanosis-affected canine melanocytesmembers
  • Nasopharyngeal sialoceles in brachycephalic dogsmembers
  • Enterococcus faecium SF68 on serum cobalamin and folate concentrationsmembers
  • Gastrointestinal eosinophilic sclerosing fibroplasia limited to the mesentery in a catmembers
  • Ion acid-base disturbances and associated mortality in dogsmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved